Exhibit (a)(5)(I)






For immediate release:                                         Media Contact:
April 15, 2008                                                 Shreya Jani
                                                               (212) 733-4889

                                                               Investor Contact:
                                                               Jennifer Davis
                                                               (212) 733-0717


                   PFIZER COMPLETES TENDER OFFER FOR SHARES OF
                          ENCYSIVE PHARMACEUTICALS INC.

NEW YORK, April 15 -- Pfizer Inc (NYSE:PFE) today announced that the subsequent
offering period of the tender offer by its wholly-owned subsidiary, Explorer
Acquisition Corp., to purchase all of the outstanding shares of common stock of
Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per
share, net to the seller in cash, without interest thereon and less any required
withholding taxes, expired as of 5:00 p.m., New York City time, on April 14,
2008. According to the final report of the depositary for the tender offer, as
of the expiration of the subsequent offering period, 69,076,466 shares,
representing approximately 85.33% of the outstanding shares of Encysive common
stock, were validly tendered and purchased pursuant to the offer.

Explorer Acquisition Corp. will acquire all of the remaining outstanding shares
of Encysive common stock by means of a merger under Delaware law. Since Explorer
Acquisition Corp. owns less than 90% of the outstanding Encysive common stock,
the "short-form" merger provisions of Delaware law will not be available for the
merger. Instead, the merger will be consummated following the mailing to
stockholders of an information statement setting forth certain information
relating to the merger and related matters. As a result of the purchase of
shares in the tender offer, Explorer Acquisition Corp. has sufficient voting
power to approve the merger without the affirmative vote of any other Encysive
stockholder. As a result of this merger, Encysive will become a wholly-owned
subsidiary of Pfizer Inc., and each share of Encysive's outstanding common stock
will be cancelled and (except for shares held by Encysive, Pfizer or by their
wholly-owned subsidiaries or by holders who properly exercise their appraisal






rights under Delaware law) converted into the right to receive $2.35 per share
in cash, without interest and less any required withholding taxes. Thereafter,
Encysive's common stock will cease to be traded on the NASDAQ Global Market.
Information regarding the merger will be mailed to Encysive stockholders who did
not tender their shares in the offer and following the consummation of the
merger instructions will be mailed to stockholders outlining the steps to be
taken to obtain the merger consideration.

                                    # # # # #



DISCLOSURE NOTICE: The information contained in this press release is as of
April 15, 2008. Except as required by law, Pfizer assumes no obligation to
update any forward-looking statements contained in this release as a result of
new information or future events or developments. Some statements in this
release may constitute forward-looking statements. Pfizer cautions that these
forward-looking statements are subject to risks and uncertainties that may cause
actual results to differ materially from those indicated in the forward-looking
statements, including the risk that the merger may not be consummated for
various reasons, including the failure to satisfy the conditions precedent to
the completion of the merger. A further list and description of risks and
uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal
year ended December 31, 2007 and in its subsequently filed reports on Form 8-K.